SOLUBIOMIX
PharmaSOLUBIOMIX is a pharmaceutical company focused on Immunology. Key products include COXANTO.
SOLUBIOMIX's Key Drugs
SOLUBIOMIX's core commercial portfolio centers on COXANTO, QUIOFIC, spanning Immunology — its most strategically important drugs approved in the last 15 years.
SOLUBIOMIX's Recent FDA Approvals
SOLUBIOMIX secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SOLUBIOMIX's Therapeutic Areas
SOLUBIOMIX's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOLUBIOMIX's Top Competitors
SOLUBIOMIX's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOLUBIOMIX Pipeline Snapshot
Active clinical trials for SOLUBIOMIX across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • COXANTO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling